David A. Thaisrivongs
David A. Thaisrivongs has a total of 414 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey T. Kuethe
Process Research and Development, Merck & Co., Inc., Rahway, NJ, USA
8 shared publications - Nadine Kuhl
Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, New Jersey 07065, United States
7 shared publications - Cheol K. Chung
Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
6 shared publications - Kai-Jiong Xiao
Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
5 shared publications - Louis-Charles Campeau
Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
5 shared publications Lushi Tan
Department of Process Research and Development
5 shared publications
Latest Publications
- 20 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 21097-21098
Correction to “Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, Through Issue Driven Fragment-Based Synthetic Assembly and SAR”
- 20 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 21097-21098
Correction to “Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, Through Issue Driven Fragment-Based Synthetic Assembly and SAR”
- Top Cited Papers
- 27 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13473-13491
Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR
Herein, we report the discovery process of enlicitide (MK-0616, compound 18), an orally active macrocyclic peptide therapeutic against PCSK9 for LDL-C reduction. To overcome development bottlenecks in a prior lead (compound 1a) in a timely manner (sulfur oxidation liability, low solubility, azido potential manufacturing hazard, and alkene isomeric complexity), we deployed a novel scalable solution-phase modular fragment assembly (North/East/South/West/tail), which allowed us to accelerate the design-make-test-analyze (DMTA) cycle and preclinical profiling. Design solutions were quickly validated through this approach (a northern lactam staple, an N-benzylamide southern spacer, an RCM-derived cross-link in conjunction with solvent-exposed motifs to modulate solubility) and delivered compounds with low picomolar potency, improved solubility, stability, and PK from which enlicitide (MK-0616, compound 18) was selected for clinical progression. This modular strategy may act as a template to accelerate late-stage issue-driven SAR in highly engineered macrocyclic peptides.
- 27 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13473-13491
Top Cited PapersDiscovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR
Herein, we report the discovery process of enlicitide (MK-0616, compound 18), an orally active macrocyclic peptide therapeutic against PCSK9 for LDL-C reduction. To overcome development bottlenecks in a prior lead (compound 1a) in a timely manner (sulfur oxidation liability, low solubility, azido potential manufacturing hazard, and alkene isomeric complexity), we deployed a novel scalable solution-phase modular fragment assembly (North/East/South/West/tail), which allowed us to accelerate the design-make-test-analyze (DMTA) cycle and preclinical profiling. Design solutions were quickly validated through this approach (a northern lactam staple, an N-benzylamide southern spacer, an RCM-derived cross-link in conjunction with solvent-exposed motifs to modulate solubility) and delivered compounds with low picomolar potency, improved solubility, stability, and PK from which enlicitide (MK-0616, compound 18) was selected for clinical progression. This modular strategy may act as a template to accelerate late-stage issue-driven SAR in highly engineered macrocyclic peptides.
- Top Cited Papers
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Top Cited PapersBiocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- 14 July 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (8) , 2076-2085
Biocatalytic Aerobic Oxidation for Large-Scale Production of trans-3-Hydroxy-l-Proline
- 14 July 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (8) , 2076-2085
Biocatalytic Aerobic Oxidation for Large-Scale Production of trans-3-Hydroxy-l-Proline
- Top Cited Papers
- 24 March 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (13) , 11036-11048
Total Synthesis of Enlicitide Decanoate
We report the total synthesis of enlicitide decanoate, an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 that is being developed for the treatment of atherosclerotic cardiovascular disease. It is a highly complex macrocyclic peptide with a significant number of nonpeptide structural elements that presents a daunting synthetic chemistry challenge. We describe the development of a convergent, efficient, and robust manufacturing process that enables the large-scale production of enlicitide.
- 24 March 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (13) , 11036-11048
Top Cited PapersTotal Synthesis of Enlicitide Decanoate
We report the total synthesis of enlicitide decanoate, an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 that is being developed for the treatment of atherosclerotic cardiovascular disease. It is a highly complex macrocyclic peptide with a significant number of nonpeptide structural elements that presents a daunting synthetic chemistry challenge. We describe the development of a convergent, efficient, and robust manufacturing process that enables the large-scale production of enlicitide.
- 26 February 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (3) , 671-677
Industry Perspective on the Selection of Regulatory Starting Materials for Synthetic Peptides
- 26 February 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (3) , 671-677
Industry Perspective on the Selection of Regulatory Starting Materials for Synthetic Peptides
- 30 May 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (6) , 2309-2316
The First GMP Synthesis of MK-2118, a Small Molecule Agonist for Stimulator of Interferon Genes
- 30 May 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (6) , 2309-2316
The First GMP Synthesis of MK-2118, a Small Molecule Agonist for Stimulator of Interferon Genes
- 24 October 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (11) , 1965-1974
Manufacturing Process Development for the Biaryl Ether Fragment of Nemtabrutinib (MK-1026)
- 24 October 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (11) , 1965-1974
Manufacturing Process Development for the Biaryl Ether Fragment of Nemtabrutinib (MK-1026)